Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia A in Italy: Characteristics and Clinical Benefits

Autor: Mario Schiavoni, Mariasanta Napolitano, Gaetano Giuffrida, Antonella Coluccia, Sergio Siragusa, Valeria Calafiore, Giuseppe Lassandro, Paola Giordano

Publikováno v: Frontiers in Medicine, Vol 6 (2019)

The current interest in recombinant factor VIII (rFVIII) products stems from the fact that they offer a technological solution to prolonging the half-life of and reducing the risk of formation of alloantibodies (inhibitors) against FVIII in treated p

Externí odkaz: https://doaj.org/article/fcd6893cb3e84ffe95975fdca512f56e

Towards a disease-associated common trait of gut microbiota dysbiosis: The pivotal role of Akkermansia muciniphila

Autor: Alessandra Russo, Loris Riccardo Lopetuso, Antonio Gasbarrini, Franco Scaldaferri, Mario Schiavoni, Valentina Petito, Andrea Quagliariello, Gianluca Ianiro, Federica Del Chierico, Matteo Neri, Lorenza Putignani, Sofia Reddel, Giovanni Cammarota

Background Gut microbiota exerts a crucial role in gastrointestinal (GI) and extra-intestinal (EI) disorders. In this context, Akkermansia muciniphila is pivotal for the maintenance of host health and has been correlated with several disorders. Aim T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc4cdfeb725353a4a84076169f2e895f
http://hdl.handle.net/10807/204169

Metamaterial architecture from a self-shaping carnivorous plant

Autor: Maria Chiara Lionetti, Simone Milan, Larissa De Paola, Miriam Ascagni, Umberto Fascio, Mario Schiavoni, Caterina A. M. La Porta, M. Beretta, Alberto Vailati, Daniel Rayneau-Kirkhope, Silvia Bonfanti, Stefano Zapperi, Ermelinda Falletta, Ausonio Tuissi, Zoe Budrikis, C. Ferrario, Maryam Hanifpour, Oleksandr Chepizhko, Alessandro Caselli

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America
Proceedings of the National Academy of Sciences of the United States of America 116 (2019): 18777–18782. doi:10.1073/pnas.1904984116
info:cnr-pdr/source/autori:La Porta C.A.M.; Lionetti M.C.; Bonfanti S.; Milan S.; Ferrario C.; Rayneau-Kirkhope D.; Beretta M.; Hanifpour M.; Fascio U.; Ascagni M.; De Paola L.; Budrikis Z.; Schiavoni M.; Falletta E.; Caselli A.; Chepizhko O.; Tuissi A.; Vailati A.; Zapperi S./titolo:Metamaterial architecture from a self-shaping carnivorous plant/doi:10.1073%2Fpnas.1904984116/rivista:Proceedings of the National Academy of Sciences of the United States of America/anno:2019/pagina_da:18777/pagina_a:18782/intervallo_pagine:18777–18782/volume:116
Proceedings of the National Academy of Sciences

Significance Understanding how carnivorous plants actuate leaf motion to capture their preys is an intriguing problem with potential applications for bio-inspired materials. Here, we show that bending of Drosera capensis leaves is programmed into its

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4453371fd3fe2c0830f422bc454ae519
https://aaltodoc.aalto.fi/handle/123456789/40576

Acquired haemophilia: experience of two Italian centres with 17 new cases

Autor: N. Ciavarella, F. Rodeghiero, Mario Schiavoni, Giancarlo Castaman, E. Di Bona

Publikováno v: Haemophilia : the official journal of the World Federation of Hemophilia. 3(3)

Summary. Acquired haemophilia is a rare but often catastrophic haemorrhagic disorder associated with a high mortality rate. No single therapeutic approach has been consistently successful and clinical experience remains mainly anecdotal. This report

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc92203797cd31221128151799918380
https://pubmed.ncbi.nlm.nih.gov/27214802

Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors

Autor: M. von Depka, Jan Astermark, H.M. van den Berg, Alessandro Gringeri, A Rocino, Mario Schiavoni, Rosario Perez Garrido, A. Villar, Jerzy Windyga, M Morado, Lorenzo G. Mantovani

Publikováno v: Haemophilia. 13:38-45

The ultimate goal of treatment for patients with inhibitory antibodies should be to permanently eradicate the inhibitor by immune tolerance induction therapy (ITI). However, ITI procedures fail in a substantial number of patients and in many countrie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e312d771949bee5ae97ae9151ae1d182
https://doi.org/10.1111/j.1365-2516.2006.01403.x